NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that plays critical roles in energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline with age, and supplementation via IV or subcutaneous injection has become a cornerstone of longevity and anti-aging clinical practice. Oral capsules are also available through compounding pharmacies as a lower-cost, at-home option, though intact NAD+ is poorly absorbed by that route.

Category
Metabolic & Longevity
Demand
High
Route
Intravenous infusion, subcutaneous injection, intramuscular injection, oral capsule
FDA status
Compounding eligibility varies; verify current FDA status before prescribing
Also known as
Nicotinamide Adenine DinucleotideNAD IVNAD InjectionOral NAD+NAD+ Capsule

How NAD+ Works

NAD+ serves as an essential coenzyme for over 500 enzymatic reactions, functioning as an electron carrier in mitochondrial oxidative phosphorylation (complexes I through IV) and as a substrate consumed by sirtuins (SIRT1-7), PARPs (poly-ADP-ribose polymerases), and CD38 [3]. Sirtuin activation by NAD+ promotes histone deacetylation, enhancing DNA repair, mitochondrial biogenesis, and anti-inflammatory gene expression [4]. PARP activity (DNA repair) and CD38 activity (immune cell signaling) both consume NAD+, creating competition for a limited substrate pool that becomes increasingly depleted with aging [3].

Clinical Evidence

Human clinical trials of NAD+ precursors (NMN and NR) have demonstrated significant elevation of blood NAD+ levels [2]. A 2021 randomized controlled trial in Science (MIB-626/NMN) showed dose-dependent NAD+ elevation and improved insulin sensitivity in overweight adults [1]. The 2018 Elysium/ChromaDex NR trial published in Nature Communications confirmed safe, sustained NAD+ elevation in healthy middle-aged and older adults [2]. Direct IV NAD+ bypasses the precursor conversion pathway, providing immediate bioavailability. Long-term outcomes data from NAD+ supplementation trials (cardiovascular events, mortality, cancer incidence) are not yet available.

Clinical Uses

  • Longevity and anti-aging protocols (cellular repair, sirtuin activation)
  • Cognitive function support and neuroprotection
  • Chronic fatigue and energy optimization
  • Addiction recovery support (alcohol, opioids)
  • Metabolic health and mitochondrial function

Patient Selection and Screening

Appropriate for patients experiencing age-related fatigue and cognitive decline [4], those with documented mitochondrial dysfunction or chronic fatigue conditions, patients in addiction recovery (particularly alcohol and opioid withdrawal support), and athletes or executives seeking cognitive and physical performance optimization. Screen for active malignancy (NAD+ role in tumor cell metabolism is complex) [3]. Patients with anxiety or insomnia should start with lower doses, as NAD+ can be stimulatory. IV protocols require adequate venous access and patient tolerance for extended infusion times.

Dosing and Administration

IV infusion: 250 to 750 mg over 2 to 4 hours for standard longevity protocols; up to 1000 to 1500 mg over 6 to 8 hours for addiction recovery loading. Start infusion slowly (first 30 minutes at reduced rate) to assess tolerance. Subcutaneous injection: 50 to 200 mg daily for home maintenance between IV sessions. Loading protocols typically include 4 to 6 IV sessions over 2 weeks, followed by monthly or bimonthly IV maintenance with daily subcutaneous injections between visits [2]. Oral capsule: 100 to 500 mg daily, often split across two doses; treat oral as a convenience or maintenance option rather than an IV substitute, since oral bioavailability of intact NAD+ is low. Reduce infusion rate immediately if patient develops chest pressure, nausea, or cramping.

Route
Intravenous infusion, subcutaneous injection, intramuscular injection, oral capsule
Protocol notes
Administered via intravenous infusion (250-1000mg over 2-4 hours) or subcutaneous injection (50-100mg). IV protocols often involve loading phases followed by maintenance. Subcutaneous formulations allow home administration. Oral capsules (100-500mg daily) are the lowest-cost home option, but NAD+ taken orally is largely broken down to its precursors (nicotinamide, NR, NMN) in the gut, so an oral protocol does not reproduce IV bioavailability.

Safety and Monitoring

Potential side effects

  • Chest tightness and pressure during IV infusion (rate-dependent; resolves with slowing infusion)
  • Nausea, abdominal cramping, and diaphoresis during IV administration
  • Headache, particularly during or after first infusion
  • Injection site pain and induration with subcutaneous formulations
  • Stimulatory effects (insomnia, anxiety) with evening dosing or high doses

Clinical considerations

  • IV administration can cause chest tightness, nausea, and cramping if infusion rate is too fast
  • Slow infusion rates (2-4 hours for 500mg+) minimize adverse effects
  • Subcutaneous formulations may cause injection site discomfort
  • Oral NAD+ is largely hydrolyzed to precursors in the gut; do not present capsules as equivalent to IV
  • Monitor for interactions with medications metabolized via NAD-dependent pathways
  • No standardized dosing guidelines; protocols vary significantly between practices

Practice Economics

NAD+ IV therapy is among the highest-revenue services in longevity medicine, with per-session pricing ranging from $500 to $1500+ depending on dose and market [3]. The combination of IV loading protocols (high-margin, in-clinic) with home subcutaneous maintenance prescriptions creates a dual revenue stream with strong patient retention. Addiction recovery programs utilizing high-dose NAD+ protocols can command premium pricing for intensive multi-day treatment packages. The extended infusion time (2 to 4+ hours) also drives ancillary revenue through bundled services during the visit.

FDA Category Status

Compounding eligibility varies; verify current FDA status before prescribing

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

What is the difference between IV and subcutaneous NAD+?

IV NAD+ provides immediate, high-dose systemic delivery but requires clinic visits (2-4 hours per infusion) and carries higher cost. Subcutaneous NAD+ allows home administration at lower doses with better patient convenience. Many practices use IV loading protocols followed by subcutaneous maintenance for cost-effectiveness and compliance.

What evidence supports NAD+ supplementation for anti-aging?

Preclinical evidence is strong, showing NAD+ supplementation restores cellular function, activates sirtuins, improves mitochondrial function, and extends healthspan in animal models. Human clinical trial data is more limited but growing. The age-related decline in NAD+ levels is well-established, providing mechanistic rationale.

How should practices structure NAD+ programs for profitability?

Successful NAD+ programs typically include initial IV loading sessions (4-6 infusions), periodic IV maintenance (monthly or quarterly), and home subcutaneous injection protocols between IV sessions. The combination of high-margin IV services and recurring subcutaneous prescriptions creates sustainable revenue.

References

  1. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229.
  2. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
  3. Rajman L, et al. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
  4. Braidy N, et al. Role of nicotinamide adenine dinucleotide and related precursors as therapeutic targets for age-related neurodegenerative diseases. Antioxid Redox Signal. 2019;30(2):251-294.

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs